Last reviewed · How we verify
Insulin lispro B
At a glance
| Generic name | Insulin lispro B |
|---|---|
| Also known as | LY275585 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site erythema
- Nausea
- Injection site pain
- Nasopharyngitis
- Procedural pain
- Hyperglycaemia
- Hypothyroidism
- Abdominal pain
- Vomiting
- Feeling hot
- Injection site discomfort
- Injection site pruritus
Key clinical trials
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (PHASE1)
- A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (PHASE1)
- A Study of Lispro Formulations in Healthy Participants (PHASE1)
- A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes (PHASE1)
- Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes (PHASE1, PHASE2)
- Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy (PHASE1)
- Effect of Splitting Mealtime Insulin Doses After Mixed Meals High in Fat and Protein (PHASE4)
- New Onset Type 1 Diabetes: Role of Exenatide (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin lispro B CI brief — competitive landscape report
- Insulin lispro B updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI